Article info
PDFClinical and epidemiological research
Extended report
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- Correspondence to Dr Lisy Wang, Department of Clinical Sciences, Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA; Lisy.Wang{at}pfizer.com
Citation
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Publication history
- Received May 2, 2014
- Revised March 5, 2015
- Accepted March 22, 2015
- First published April 22, 2015.
Online issue publication
June 08, 2018
Article Versions
- Previous version (8 June 2018).
- Previous version (8 June 2018).
- You are viewing the most recent version of this article.
- latest version (8 June 2018).
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/